12:00 AM
 | 
Jul 02, 2007
 |  BioCentury  |  Finance

Better, but not leading

2Q Stock Wrap-Up

Better, but not leading

April came in like a lion, as U.S. stock markets surged. But by mid-May, the broader markets - and biotech along with them - had turned tail.

Still, the BioCentury 100 ended the quarter up 5% and the first half up 6%. The BioCentury benchmark also broke 1,800 for the first time since the genomics bubble. Nevertheless, the index finished behind the broader markets: the S&P, NASDAQ and Dow Jones gained 6%, 7% and 9%, respectively, in 2Q07 (see "Index Performance").

The BioCentury London Index eroded by 4% last quarter, while the BioCentury Europe Index was off 2%. Both were lackluster in the first quarter as well (see "London...

Read the full 562 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >